Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Business Strategies Sales & Earnings

Top 10 Drugs Of 2020: #5 Stelara

Seizing The Opportunity In IBD

  • Analysis

You may also be interested in...



Samsung Bioepis Pushes Stelara Rival Into Phase I

Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.

J&J Forecasts Strong Pharma Growth In 2021, But No COVID-19 Vaccine Update

Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.

Celltrion Keeps Pace With Ustekinumab Rivals

Celltrion is looking to keep its ustekinumab biosimilar program in step with those of rival developers, after announcing the start of Phase III trials for its CT-P43 candidate.

Table

View full table

Related Content

Generics Bulletin
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Commercial Business Strategies Sales & Earnings
Latest News

Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake

Prometheus Phase II Data For Novel TL1A Inhibitor Impresses On Efficacy

Novartis’ Kisqali Could Challenge Pfizer’s Ibrance After Phase II First-Line Aggressive Breast Cancer Success

Safety Could Differentiate Nkarta’s CAR-NK Cell Therapy

See All
UsernamePublicRestriction

Register

SC144175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By